Question 1

Which countries lead BRCA gene mutations in cancer research?

Accepted Answer

By volume, the United States and the United Kingdom publish the most (2.5k and 440 works in 2022-now).

Question 2

Which institutions lead BRCA gene mutations in cancer research?

Accepted Answer

By volume in 2022-now, Harvard University publishes the most BRCA gene mutations in cancer research, followed by University of North Carolina at Chapel Hill and National Institutes of Health.

Question 3

Who are the leading researchers in BRCA gene mutations in cancer?

Accepted Answer

The most-cited researchers publishing on BRCA gene mutations in cancer include David Moher, Douglas G. Altman and Ahmedin Jemal.

Question 4

Where is BRCA gene mutations in cancer research done?

Accepted Answer

The largest centres of BRCA gene mutations in cancer research in 2022-now are New York (United States), London (United Kingdom), Boston (United States) and Philadelphia (United States).

Question 5

Where is the best place to study BRCA gene mutations in cancer?

Accepted Answer

Among universities, judged by research, Harvard University, University of Cambridge and Queen Mary University of London score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is BRCA gene mutations in cancer research growing?

Accepted Answer

Output in 2022-2025 was 9% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are BRCA gene mutations in cancer.

Question 7

What are the most cited papers in BRCA gene mutations in cancer?

Accepted Answer

The most cited paper in BRCA gene mutations in cancer is "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology" (Sue M. Richards, Nazneen Aziz, Sherri J. Bale et al., 2015), with 33,443 citations. Next come "A Gene-Expression Signature as a Predictor of Survival in Breast Cancer" (6,562) and "A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1" (6,134).